1. Home
  2. HBT vs MPLT Comparison

HBT vs MPLT Comparison

Compare HBT & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HBT Financial Inc.

HBT

HBT Financial Inc.

HOLD

Current Price

$33.29

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$36.56

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBT
MPLT
Founded
1920
2018
Country
United States
United States
Employees
N/A
133
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
HBT
MPLT
Price
$33.29
$36.56
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$30.75
$32.67
AVG Volume (30 Days)
178.5K
563.2K
Earning Date
04-27-2026
05-28-2026
Dividend Yield
3.29%
N/A
EPS Growth
7.96
N/A
EPS
0.34
N/A
Revenue
N/A
N/A
Revenue This Year
$35.73
N/A
Revenue Next Year
$7.01
N/A
P/E Ratio
$95.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.36
$12.24
52 Week High
$33.70
$40.43

Technical Indicators

Market Signals
Indicator
HBT
MPLT
Relative Strength Index (RSI) 64.46 54.74
Support Level $31.20 $26.20
Resistance Level $33.40 $40.43
Average True Range (ATR) 0.83 2.75
MACD -0.05 -0.46
Stochastic Oscillator 84.56 35.78

Price Performance

Historical Comparison
HBT
MPLT

About HBT HBT Financial Inc.

HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: